Solis Agrosciences

Solis Agrosciences is a technology company.

Active

Updated: Dec 9, 2025 ·

Recent News & Mentions

Feb 1, 2025FundingSolis Agrosciences - Series A Jul 1, 2023FundingSolis Agrosciences - Series A Nov 1, 2022FundingSolis Agrosciences - Series A

Financial History

Solis Agrosciences has raised $4.5M across 3 funding rounds. Most recently, it raised $500K Series A in February 2025.

Total Raised

$4.5M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Feb 1, 2025	$500K Series A	Cultivation Capital, VentureSouth
Jul 1, 2023	$1.0M Series A	Cream City Venture Capital, FINTOP Capital, Startup Mavericks, The Artemis Fund, Baron Davis
Nov 1, 2022	$3.0M Series A	Cream City Venture Capital, FINTOP Capital, Startup Mavericks, The Artemis Fund, Baron Davis

Financial History

Solis Agrosciences has raised $4.5M across 3 funding rounds.

Total Raised

$4.5M

Valuation

N/A

Deep Dive

High-Level Overview

Solis Agrosciences is an AgTech company founded in 2021 (with some sources noting 2022) in St. Louis, Missouri, providing R&D services to accelerate innovation for ag biotech startups.[1][2][3] Its core offering, Plant Pipeline as a Service, delivers end-to-end solutions including plant transformation, gene editing, cloning, growth, seed production, greenhouse operations, molecular analysis, and bioinformatics, initially focused on soy and corn but expanding based on demand.[1][2][3][4] The company serves early-stage AgTech innovators addressing food security, climate resilience, and sustainability by outsourcing complex processes, equipment, and expertise that startups often lack, enabling faster commercialization while retaining full IP ownership.[2][3] With $3.14M raised in a Series A round two years ago (primarily equity from BioGenerator Ventures) and recent expansions like acquiring a genomics platform and licensing Pairwise's CRISPR tools, Solis demonstrates strong growth momentum in a sector critical to global agriculture.[1][4][5]

Origin Story

Solis Agrosciences was launched in 2021 by industry veterans Mary Fernandes (President, former Monsanto executive), Martha Schlicher, and Dave Smoller, all longtime ag and biotech leaders, to bridge gaps for startups lacking corporate-level R&D infrastructure.[2][4] Backed initially by BioGenerator Ventures and operating from the BioGenerator in Helix Labs within St. Louis' 39 North Innovation District—a hub for ag biotech—the idea emerged from recognizing that even funded startups struggle with proprietary processes, specialized equipment, and talent for genetically modified plant development.[2][4] Early traction came via its fee-for-service model, quickly attracting partners like ZeaKal, Amfora, and Harpe Bioherbicide Solutions, with pivotal moments including 2024 leadership appointments, pre-seed investments for clients, and 2025 announcements for expanded genome editing, transformation, sequencing, and a strategic genAI partnership with Ordaos.[3][4]

Core Differentiators

End-to-End Plant Pipeline as a Service: Integrates cloning, transgenic/gene-edited plant generation, seed production, greenhouse space, germplasm access, validation, molecular tools, and regulatory connections—acting like an in-house team for startups without the overhead.[2][3]
Startup-Tailored Expertise: Founded by ex-Monsanto and biotech execs, offers deep industry knowledge, flexible solutions, and impeccable service, with testimonials praising it as "indispensable" for exceeding expectations in speed and results.[2][3][4]
IP Protection and Scalability: Clients retain all intellectual property; services expand from soy/corn to other species, plus recent genomics acquisitions and CRISPR licensing from Pairwise for genotyping, sequencing, and bioinformatics.[4][5]
Ecosystem Access: Provides raw materials, third-party regulatory support, and connections to talent/infrastructure, making innovation "faster and simpler" in a capital-intensive field.[2][3]

Role in the Broader Tech Landscape

Solis rides the AgTech boom, fueled by urgent needs for climate-resilient, disease-resistant crops amid global food insecurity, population growth, and supply chain waste—trends amplified by advances in CRISPR, AI-driven genome editing, and sustainable farming.[1][2][3] Timing is ideal post-2021 launch, as regulatory shifts (e.g., eased gene-editing rules) and investor interest in AgTech (2,498 companies tracked) lower barriers, while St. Louis' biotech cluster provides a fertile base.[1][2][4] Market forces like rising demand for bio-based crop protection and plant-based proteins favor Solis, which democratizes high-end R&D for startups competing with giants like CHS or innovators like Phytoform and Tropic.[1] By supporting firms like ZeaKal (PhotoSeed for productivity) and Amfora (protein revolution), Solis influences the ecosystem as a force multiplier, speeding discoveries that enhance crop hardiness, reduce waste, and tackle sustainability challenges.[3][4]

Quick Take & Future Outlook

Solis is poised for expansion with its 2025 genomics push, genAI ties, and service scaling, potentially dominating as the go-to R&D partner for AgTech amid surging demand for resilient crops.[4] Trends like AI-genomics integration, regulatory tailwinds, and climate-driven innovation will propel it, evolving its role from service provider to ecosystem orchestrator—linking startups to commercialization at warp speed. This positions Solis to supercharge the next wave of agricultural breakthroughs, turning St. Louis' "Plant Pipeline" into a global conduit for feeding the planet sustainably.[2][3][4]

Sources

Frequently Asked Questions

How much funding has Solis Agrosciences raised?

Solis Agrosciences has raised $4.5M in total across 3 funding rounds.

Who are Solis Agrosciences's investors?

Solis Agrosciences's investors include Cultivation Capital, VentureSouth, Cream City Venture Capital, FINTOP Capital, Startup Mavericks, The Artemis Fund, Baron Davis.